Chapters Transcript Video Lakshmi Nayak, MD Discusses CNS Lymphoma Back to Symposium CNS Lymphoma research at ASCO24: Dana-Farber's Lakshmi Nayak, MD, details findings of a pilot study showing a CAR T-cell therapy has shown promise and is safe and well-tolerated in treating patients with relapsed, treatment-resistant CNS lymphoma. The key takeaway of this study was that uh we definitely found that A L was found to be safe uh as a treatment for CNS lymphoma patients. Uh We didn't see any increased risk in terms of cytokine release syndrome, as well as the neurotoxicity or cerebral edema, which was a concern. Additionally, we found that it has extremely promising efficacy signal in a heavily prorated population. And several of our patients had undergone an autologous stem cell transplant. Uh and several other patients had had multiple lines of therapy. In addition to having high efficacy or response rates, we found high durability, which is incredibly promising. Published June 13, 2024 Created by Related Presenters Lakshmi Nayak, MD Neuro-oncology View full profile
